Health

Results: 4849-4860 of 8221

PR Newswire associated0

Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform

Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY® (approved as HANSIZHUANG in China) in European markets as First-Line Treatment for adult patients with Extensive-Stage Small Cell Lung Cancer

PR Newswire associated0

European Wellness Unveils Premier Medical Wellness Center in Kota Kinabalu, Sabah: A Landmark in Global Healthcare

Lenzing's VEOCEL™ builds awareness in combating plastic pollution highlighted at UN's SEA of Solutions 2024

The Lewy Body Society associated0

Lewy Body Society is calling for greater awareness, early diagnosis and quality support for the disease on World Alzheimer's Day

UNION therapeutics to present orismilast Phase 2b results in atopic dermatitis as a late-breaking oral presentation at the EADV Congress 2024

The parable of the lost sheep mirrors our journey to find a solution for Duchenne Muscular Dystrophy (DMD), a rare disease. Our global interdisciplinary team is fortunate to have been gifted with Neu REFIX, whose hidden potentials of beneficial immune modulation, we unravelled by extensive preclinical and clinical studies. This gives hope to DMD patients for its potentials in improving their quality of life by halting the disease progress. Like the shepherd when he found the lost sheep, our joy knew no bounds, when we got encouraging outcome in DMD research. Now on receiving orphan drug and rare paediatric disease designations from US FDA, while it’s time to rejoice, we have miles to go until it reaches every deserving patient after an approval, the final goal. We are open to collaborate with likeminded institutes to reach the goal. Further insights have revealed the potentials of Neu REFIX in Psoriasis, auto-immune diseases and in Multiple Sclerosis by gut microbiome reconstitution. (Graphic: Business Wire)

Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy

Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering

PR Newswire associated0

Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference

Business Wire embedded0

Neuraptive Therapeutics Announces Presentation of Phase 2 Topline Interim Results for NTX-001 at the 2024 American Society for Surgery of the Hand (ASSH) Annual Meeting

Novotech is a Great Place to Work Certified in the USA (Graphic: Business Wire)

Novotech Earns Great Place to Work® Certification in the United States

PR Newswire associated0

TraceLink Releases Opus Solution Environment, the First No-Code Environment for Visually Building Multi-Enterprise Supply Chain Solutions